drugset / Trial / NCT04413253

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

NCT04413253

Non-randomizedCrossoverSingle-blindTreatment

Summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in patients with dry eye who are beginning treatment with Xiidra (lifitegrast ophthalmic solution) to reduce the signs and symptoms of dry eye disease.

Timeline

Start
2020-08-01
Primary completion
2022-04-11
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 0.4 mg Other
Comparator Lifitegrast Unknown 5 % Other

Indications